Recognizing and improving patient nonadherence to statin therapy
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Despite landmark trials demonstrating the benefits of statin therapy for lipid lowering and in the primary and secondary prevention of acute coronary events, many patients do not adhere to medication regimens. Although incremental gains have been made in lowering the absolute levels of total serum cholesterol in the general population, only one third of treated patients are achieving their lipid goals, with fewer than 20% of patients with cardiovascular disease at their target lipid goals. Only half of patients continue taking statins prescribed to them at 6 months, and only 30% to 40% continue taking them at 1 year. Predictors of poor adherence to statins are described, such as female gender and low socioeconomic status. Approaches that are physician focused and patient centered, such as frequent follow-up and serum lipid testing and better education of patients about cardiovascular disease, are suggested to offset a major impediment to achieving the full therapeutic outcomes promised by clinical trials.
- Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics — 2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2007, 115:e69–e171. CrossRef
- Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937–952. CrossRef
- Scandinavian Simvastatin Survival Study Investigators: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389. CrossRef
- Shepherd R, Cobb SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307. CrossRef
- Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996, 335:1001–1009. CrossRef
- LIPID Investigators: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349–1357. CrossRef
- Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622. CrossRef
- LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346. CrossRef
- Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.
- Carroll MD, Lacher DA, Sorlie PD, et al.: Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 2005, 294:1773–1781. CrossRef
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143–3421.
- Simmons LA, Levis G, Simons J: Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996, 164:208–211.
- Avorn J, Monette J, Lacour A, et al.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458–1462. CrossRef
- Benner JS, Glynn RJ, Mogun H, et al.: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455–461. CrossRef
- Frolkis JP, Pearce JL, Nambi V, et al.: Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002, 113:625–629. CrossRef
- Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288:462–467. CrossRef
- Blackburn DF, Dobson RT, Blackburn JL: Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005, 25:1035–1043. CrossRef
- Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671–2676. CrossRef
- Bandolier S: Patient compliance with statins. Available at http://www.jr2.ox.ac.uk/ bandolier/ booth/cardiac/patcomp.html. Accessed September 25, 2007.
- Choudhry NK, Avorn J, Antman EM, et al.: Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood) 2007, 26:186–194. CrossRef
- Thiebaud P, Patel BV, Nichol MB: The demand for statin: the effect of copay on utilization and compliance. Health Econ 2007, In press.
- Gibson TB, Mark TL, Axelson K, et al.: Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006, 12:SP11–SP19.
- Schultz JS, O’Donnell JC, McDonough KL, et al.: Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005, 11:306–312.
- Schneeweiss S, Patrick AR, Maclure M, et al.: Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 2007, 115:2128–2135. CrossRef
- Wei L, MacDonald TM, Watson AD, Murphy MJ: Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007, 16:385–392. CrossRef
- Brookhart MA, Patrick AR, Schneeweiss S, et al.: Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007, 167:847–852. CrossRef
- Benner JS, Tierce JC, Ballantyne CM, et al.: Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004, 22(Suppl 3):13–23.
- Benner JS, Pollack MF, Smith TW, et al.: Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005, 62:1468–1475. CrossRef
- Pearson T, Kopin L: Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. Prev Cardiol 2003, 6:204–211. CrossRef
- Weymiller AJ, Montori VM, Jones LA, et al.: Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med 2007, 167:1076–1082. CrossRef
- Rasmussen JN, Chong A, Alter DA: Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177–186. CrossRef
- Kirsch IS, Jungeblut A, Jenkins L, Kolstad A: Adult Literacy in America: A First Look at the Findings of the National Adult Literacy Survey, edn 2. Washington, DC: Department of Education, Office of Educational Research and Improvement; 1993.
- Healthy People 2010, edn 2. Washington, DC: Department of Health and Human Services; 2000.
- Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409–1412. CrossRef
- Thiebaud P, Patel BV, Nichol MB, Berenbeim DM: The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005, 11:670–674.
- Perreault S, Blais L, Dragomir A, et al.: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005, 61:667–674. CrossRef
- Chapman RH, Benner JS, Petrilla AA, et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005, 165:1147–1152. CrossRef
- Cubeddu LX, Seamon MJ: Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 2006, 26:1288–1296. CrossRef
- Fleisher LA, Beckman JA, Brown KA, et al.: ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery.) Circulation 2007, In press.
- Petrilla AA, Benner JS, Battleman DS, et al.: Evidence-based interventions to improvepatient compliance with anti-hypertensive and lipid-lowering medications. Int J Clin Pract 2005, 59:1441–1451. CrossRef
- Lipitor: Warnings, Liver Dysfunction. Physicians’ Desk Reference, edn 61. Montvale, NJ: Thomson PDR; 2485.
- Bonow RO, Smaha LA, Smith SC Jr, et al.: World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002, 106:1602–1605. CrossRef
- Brookhart MA, Patrick AR, Dormuth C, et al.: Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007, 166:348–354. CrossRef
- Chaudhry HJ, Grieco AJ, Macklis RM, et al.: Fundamentals of Clinical Medicine, edn 4. Philadelphia: Lippincott Williams & Wilkins; 2004:33–39.
- Recognizing and improving patient nonadherence to statin therapy
Current Atherosclerosis Reports
Volume 10, Issue 1 , pp 19-24
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links